Analysis of a successful HCV‐specific CD8+ T cell response in patients with recurrent HCV‐infection after orthotopic liver transplantation

Norbert Hubert Gruener, Maria‐Christina Jung, Axel Ulsenheimer, Joern Tilman Gerlach, Reinhart Zachoval, Helmut Michael Diepolder, Gustavo Baretton, Rolf Schauer, Gerd Rudolf Pape, Carl Albrecht Schirren – 19 November 2004 – Virus‐specific CD8+ T cells play a major role in antiviral immune defenses; their significance in the transplant setting, however, is unclear.

Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C

Mitsugi Shimoda, Rafik M. Ghobrial, Ian C. Carmody, Dean M. Anselmo, Douglas G. Farmer, Hasan Yersiz, Pauline Chen, Sherfield Dawson, Francisco Durazo, Steve Han, Leonard I. Goldstein, Sammy Saab, Jonathan Hiatt, Ronald W. Busuttil – 19 November 2004 – The efficacy of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is not well defined. This study examines the variables that may determine the outcome of OLT for HCC in HCV patients. From 1990 to 1999, 463 OLTs were performed for HCV cirrhosis.

The transplanted liver graft is capable of clearing asymmetric dimethylarginine

Michiel P.C. Siroen, Michiel C. Warlé, Tom Teerlink, Robert J. Nijveldt, Ernst J. Kuipers, Herold J. Metselaar, Hugo W. Tilanus, Dirk J. Kuik, Joost R.M. van der Sijp, Sybren Meijer, Ben van der Hoven, Paul A.M. van Leeuwen – 19 November 2004 – Asymmetric dimethylarginine (ADMA) has been recognized as an endogenous inhibitor of the arginine–nitric oxide (NO) pathway. Its concentration is tightly regulated by urinary excretion and degradation by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which is highly expressed in the liver.

Combined orthotopic heart and liver transplantation: The need for exception status listing1

Paige M. Porrett, Shashank S. Desai, Kathleen J. Timmins, Carol R. Twomey, Seema S. Sonnad, Kim M. Olthoff – 19 November 2004 – Through May 2004, 33 combined orthotopic heart‐liver transplants (OHT/OLT) have been performed nationwide. No published data exist to date regarding outcomes of patients awaiting such transplants, although progression of two organ disease processes may contribute to premature death for waiting patients.

Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection

Guy W. Neff, Christopher B. O'Brien, Jose Nery, Norah J. Shire, Seigo Nishida, Julia delaGarza, Marzia Montalbano, Kamran Safdar, Phillip Ruiz, Eric Rideman, Jose A. Gascon, Andreas G. Tzakis, Juan Madariaga, Steven M. Rudich – 19 November 2004 – Hepatitis C virus (HCV) is becoming the most common indication for liver retransplantation (ReLTx). This study was a retrospective review of the medical records of liver transplant patients at our institution to determine factors that would identify the best candidates for ReLTx resulting from allograft failure because of HCV recurrence.

Hepatocellular proliferation and changes in microarchitecture of right lobe allografts in adult transplant recipients

Ruoqing Huang, Thomas D. Schiano, May Jennifer Amolat, Charles M. Miller, Swan N. Thung, Romil Saxena – 19 November 2004 – Imaging studies show complete restoration of liver volume in adult recipients of right lobe allografts within 2–3 weeks of living donor transplantation (LDLT). However, it is not known if this growth is associated with restoration of hepatic microarchitecture. We compared 21 biopsies without significant pathology from LDLT recipients with 23 biopsies from adult recipients of cadaveric donor liver transplantation (CDLT) performed within 3 months of transplantation.

Living donor liver transplant with clinical tolerance, laboratory evidence of chimerism, and spontaneous clearance of HBV

James J. Stone, Seong‐Hwan Chang, Pamela M. Kimball, R. Todd Stravitz, Robert A. Fisher – 20 October 2004 – We present a case of functional and histopathologic tolerance, chimerism, and spontaneous clearance of HBV in a patient four years after living donor liver transplant (LDLT). A 19‐year‐old male patient underwent a LDLT for HBV cirrhosis. He voluntarily ceased immunosuppression and antiviral therapy after 6 months. He is now four years status post transplant without any episodes of rejection or clinical manifestation of liver disease.

Ability to pay and geographical proximity influence access to liver transplantation even in a system with universal access

P. Aiden McCormick, Marie O'Rourke, Deirdre Carey, Marie Laffoy – 20 October 2004 – Ireland, in common with many countries, has a mixed private and public health care system. Concern has been expressed that this system may lead to inequity in access to medical treatment. To investigate this concern, all contacts and first admissions to the national liver transplant unit were identified between April 1, 2000, and March 31, 2002. The effects of private health insurance and area of residence on the likelihood of receiving a liver transplant were assessed.

Posttransplant survival in pediatric fulminant hepatic failure: The SPLIT experience

Prabhakar Baliga, Sergio Alvarez, Anne Lindblad, Lan Zeng – 20 October 2004 – Pediatric patients with fulminant hepatic failure (FHF) tend to be the sickest and have the most urgent need for a liver transplant. The purpose of this analysis was to identify factors associated with posttransplant survival in this subset of patients. Data on all FHF patients registered in the Studies of Pediatric Liver Transplantation (SPLIT) registry from 1995 to 2002 were analyzed. Demographics such as age, gender, race, weight, and etiology of liver disease were recorded.

Subscribe to